- Email: [email protected]
Online future of The Lancet Infectious Diseases review papers
Comment
Glenn Tillotson
1
2941 Honeymead Road, Downingtown, PA 19335, USA [email protected] I am a consultant to the pharmaceutical industry, but I have not received any payment for writing this Comment.
2
Review on antimicrobial resistance. Securing new drugs for future generations: the pipeline for antibiotics. Chaired by Jim O’Neill. May, 2015. http://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS% 20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf (accessed May 17, 2015). Ehrlich P. International address in pathology. BMJ 1913; 2: 353–59.
Online future of The Lancet Infectious Diseases review papers When The Lancet Infectious Diseases was launched almost 14 years ago it was as a review journal. That situation changed in August, 2010, when the journal began publishing original research Articles. As a consequence of publishing original research, the review-type papers (Reviews, Personal Views, Historical Reviews, Series, Commissions, and Grand Rounds) had to surrender some of the journal space and editorial effort they had enjoyed previously. Thus, in 2009, the last full year as a review-only journal, we published 61 review-type papers, whereas in 2014 we published 38 such papers, and 67 research Articles. Recognising that the time has long-since passed when the space constraints of a print journal should limit the number of review-type papers we publish, we have decided to make such papers available exclusively online. This change will be phased in gradually, such that review-type papers submitted from July 1, 2015, will be eligible only for online publication. Review-type papers will continue to be published online-first ahead of issue publication, will be indexed by PubMed and similar databases, and will count towards Impact Factor calculations.
760
With this change in policy we hope to increase the number of review-type papers published by the journal, limited only by our editorial resources. With most readers accessing the journal online via internet searches, email alerts, or social media, our new policy recognises the fact that it is the website—rather than print edition—that is the definitive version of The Lancet Infectious Diseases. Subscribers to the print edition will continue to be able to access review-type papers be activating their complimentary online subscription. When our colleagues at The Lancet Oncology decided to make their review-type papers available exclusively online in 2012, downloads of such papers increased by more than 40% over the next year. With this precedent in mind, we are confident of continuing our record of publishing high-quality review-type papers in the journal. For regular updates of online publication, follow our Twitter account @TheLancetInfDis. John McConnell The Lancet Infectious Diseases, 125 London Wall, London EC2Y 5AS, UK
www.thelancet.com/infection Vol 15 July 2015
Glenn Tillotson
1
2941 Honeymead Road, Downingtown, PA 19335, USA [email protected] I am a consultant to the pharmaceutical industry, but I have not received any payment for writing this Comment.
2
Review on antimicrobial resistance. Securing new drugs for future generations: the pipeline for antibiotics. Chaired by Jim O’Neill. May, 2015. http://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS% 20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf (accessed May 17, 2015). Ehrlich P. International address in pathology. BMJ 1913; 2: 353–59.
Online future of The Lancet Infectious Diseases review papers When The Lancet Infectious Diseases was launched almost 14 years ago it was as a review journal. That situation changed in August, 2010, when the journal began publishing original research Articles. As a consequence of publishing original research, the review-type papers (Reviews, Personal Views, Historical Reviews, Series, Commissions, and Grand Rounds) had to surrender some of the journal space and editorial effort they had enjoyed previously. Thus, in 2009, the last full year as a review-only journal, we published 61 review-type papers, whereas in 2014 we published 38 such papers, and 67 research Articles. Recognising that the time has long-since passed when the space constraints of a print journal should limit the number of review-type papers we publish, we have decided to make such papers available exclusively online. This change will be phased in gradually, such that review-type papers submitted from July 1, 2015, will be eligible only for online publication. Review-type papers will continue to be published online-first ahead of issue publication, will be indexed by PubMed and similar databases, and will count towards Impact Factor calculations.
760
With this change in policy we hope to increase the number of review-type papers published by the journal, limited only by our editorial resources. With most readers accessing the journal online via internet searches, email alerts, or social media, our new policy recognises the fact that it is the website—rather than print edition—that is the definitive version of The Lancet Infectious Diseases. Subscribers to the print edition will continue to be able to access review-type papers be activating their complimentary online subscription. When our colleagues at The Lancet Oncology decided to make their review-type papers available exclusively online in 2012, downloads of such papers increased by more than 40% over the next year. With this precedent in mind, we are confident of continuing our record of publishing high-quality review-type papers in the journal. For regular updates of online publication, follow our Twitter account @TheLancetInfDis. John McConnell The Lancet Infectious Diseases, 125 London Wall, London EC2Y 5AS, UK
www.thelancet.com/infection Vol 15 July 2015